SZodixStudyAcademic Library
ShelvesOpen access
Study · an open academic library·Metadata from OpenAlex (CC0)·Shelves·OpenAlex metadata, de-duplicated
Virtual drug discovery and development for neglected diseases through public–private partnerships
5 references·16 citing·36 second hop
Virtual drug discovery and development for neglected diseases through public–private partnerships (2003)Virtual drug discovery and development fo…The price of innovation: new estimates of drug development costs (2003)The price of innovation: new …Strategic emphases for tropical diseases research: a TDR perspective (2002)Strategic emphases for tropic…Drug development for neglected diseases: a deficient market and a public-health policy failure (2002)Drug development for neglecte…Reaching Maturity — 25 Years of the TDR (2000)Reaching Maturity — 25 Years …Cost of innovation in the pharmaceutical industry (1991)Cost of innovation in the pha…Exploring different approaches to improve the success of drug discovery and development projects: a review (2020)Exploring different approache…Why miltefosine—a life-saving drug for leishmaniasis—is unavailable to people who need it the most (2018)Why miltefosine—a life-saving…Managing risks in public-private partnership formation projects (2018)Managing risks in public-priv…Responsibilization and MNC–Stakeholder Engagement: Who Engages Whom in the Pharmaceutical Industry? (2017)Responsibilization and MNC–St…Are public-private partnerships the solution to tackle neglected tropical diseases? A systematic review of the literature (2017)Are public-private partnershi…A means of improving public health in low- and middle-income countries? Benefits and challenges of international public–private partnerships (2017)A means of improving public h…The Pharmaceutical Commons (2014)The Pharmaceutical CommonsThe mismatch between the health research and development (R&D) that is needed and the R&D that is undertaken: an overview of the problem, the causes, and solutions (2013)The mismatch between the heal…priority Medicines for Europe and the World: 2013 update (2013)priority Medicines for Europe…Integrating Infrastructure and Clinical Management in PPPs for Health Care (2013)Integrating Infrastructure an…Social engineering for virtual 'big science' in systems biology (2011)Social engineering for virtua…Advancing Drug Innovation for Neglected Diseases—Criteria for Lead Progression (2009)Advancing Drug Innovation for…Public-private partnerships: an overview (2005)Public-private partnerships: …Public-private partnership: from there to here (2005)Public-private partnership: f…Priority medicines for Europe and the world (2004)Priority medicines for Europe…Finding Cures for Tropical Diseases: Is Open Source an Answer? (2004)Finding Cures for Tropical Di…Open Innovation: The New Imperative for Creating and Profiting from Technology (2003)The selection and use of essential medicines. (2004)Prevalence, Severity, and Comorbidity of 12-Month DSM-IV Disorders in the National Comorbidity Survey Replication (2005)Balancing early market access to new drugs with the need for benefit/risk data: a mounting dilemma (2008)Access to Medications for Cardiovascular Diseases in Low- and Middle-Income Countries (2016)Why do firms do basic research (with their own money)? (1990)Inalienable Possessions (1992)The sociology of expectations in science and technology (2006)A Tidal Wave of Inevitable Data? Assetization in the Consumer Genomics Testing Industry (2019)International Ties at Peripheral Sites: Co-producing Social Processes and Scientific Knowledge in Latin America (2019)When more data means better results: Abundance and scarcity in research collaborations in epigenetics (2020)Estimating The Cost Of New Drug Development: Is It Really $802 Million? (2006)Human Development Report 2001: Making new technologies work for human development (2001)Intellectual property rights, the WTO and developing countries: the TRIPS agreement and policy options (2001)25 years of the WHO essential medicines lists: progress and challenges (2003)HUMAN RIGHTS AND GLOBAL HEALTH: A RESEARCH PROGRAM (2005)The drug and vaccine landscape for neglected diseases (2000–11): a systematic assessment (2013)Conditional logit analysis of qualitative choice behavior (1972)Qualitative Response Models: A Survey (1994)Sources and Financial Consequences of Radical Innovation: Insights from Pharmaceuticals (2003)The cost of biopharmaceutical R&D: is biotech different? (2007)Essential medicines for universal health coverage (2016)Exploring the knowledge filter: How entrepreneurship and university–industry relationships drive economic growth (2006)Lessons from 60 years of pharmaceutical innovation (2009)Intellectual property policies in early-phase research in public–private partnerships (2016)The economic case for precision medicine (2018)Combatting neo-Colonialism in Health Research: What can Aboriginal Health Research Ethics and Global Health Research Ethics Teach Each Other? (2021)The Anatomy of Market Failure (1958)Access to Essential Drugs in Poor Countries (1999)Why is big Pharma getting out of antibacterial drug discovery? (2003)How to improve R&D productivity: the pharmaceutical industry's grand challenge (2010)The productivity crisis in pharmaceutical R&D (2011)Strategic emphases for tropical diseases research: a TDR perspective (2002)Can the pharmaceutical industry reduce attrition rates? (2004)Clinical development success rates for investigational drugs (2014)Innovation in the pharmaceutical industry: New estimates of R&D costs (2016)
this work references cited by second hop

References

  • 2003The price of innovation: new estimates of drug development costs4,264 cited
  • 2002Drug development for neglected diseases: a deficient market and a public-health policy failure895 cited
  • 1991Cost of innovation in the pharmaceutical industry763 cited
  • 2000Reaching Maturity — 25 Years of the TDR120 cited
  • 2002Strategic emphases for tropical diseases research: a TDR perspective103 cited

Cited by

  • 2004Priority medicines for Europe and the world244 cited
  • 2020Exploring different approaches to improve the success of drug discovery and development projects: a review228 cited
  • 2009Advancing Drug Innovation for Neglected Diseases—Criteria for Lead Progression199 cited
  • 2018Why miltefosine—a life-saving drug for leishmaniasis—is unavailable to people who need it the most162 cited
  • 2013priority Medicines for Europe and the World: 2013 update140 cited
  • 2014The Pharmaceutical Commons118 cited
  • 2004Finding Cures for Tropical Diseases: Is Open Source an Answer?116 cited
  • 2018Managing risks in public-private partnership formation projects105 cited
  • 2005Public-private partnerships: an overview105 cited
  • 2013The mismatch between the health research and development (R&D) that is needed and the R&D that is undertaken: an overview of the problem, the causes, and solutions

Only edges whose both ends are imported exist here. Widen the year window, or show the whole map. Back to the work

95 cited
  • 2005Public-private partnership: from there to here90 cited
  • 2017Are public-private partnerships the solution to tackle neglected tropical diseases? A systematic review of the literature64 cited
  • 2017A means of improving public health in low- and middle-income countries? Benefits and challenges of international public–private partnerships53 cited
  • 2011Social engineering for virtual 'big science' in systems biology40 cited
  • 2013Integrating Infrastructure and Clinical Management in PPPs for Health Care40 cited
  • 2017Responsibilization and MNC–Stakeholder Engagement: Who Engages Whom in the Pharmaceutical Industry?27 cited